A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Disease Sites:

Not Available

Staging:

Phase II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

BMS-986393

Principal Investigator(s):

Baljevic, Muhamed

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

08-11-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTCTT23527

National Clinical Trial ID:

NCT06297226

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available